Published in Cancer Res on December 08, 2010
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med (2016) 1.69
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer (2013) 1.31
Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer (2012) 1.28
Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract (2012) 1.26
Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol (2015) 1.14
Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem (2012) 1.12
Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res (2014) 1.02
Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Des (2012) 0.98
BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther (2014) 0.98
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep (2015) 0.97
Magnetization transfer MRI in pancreatic cancer xenograft models. Magn Reson Med (2011) 0.95
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther (2013) 0.95
Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res (2013) 0.88
Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med (2013) 0.87
Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer (2014) 0.86
Quantitative magnetization transfer MRI of desmoplasia in pancreatic ductal adenocarcinoma xenografts. NMR Biomed (2013) 0.86
Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PLoS One (2013) 0.83
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget (2016) 0.83
A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. Lab Chip (2013) 0.82
Thiol-ene hydrogels as desmoplasia-mimetic matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance. Biomaterials (2014) 0.81
A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of MT1-MMP via the Wnt signaling pathway. Oncol Lett (2014) 0.81
Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol (2016) 0.81
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J (2015) 0.81
Ethanol differentially regulates snail family of transcription factors and invasion of premalignant and malignant pancreatic ductal cells. J Cell Biochem (2011) 0.80
HMGA2 induces epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells. Oncol Lett (2013) 0.80
Snail cooperates with Kras G12D in vivo to increase stem cell factor and enhance mast cell infiltration. Mol Cancer Res (2014) 0.80
Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer (2016) 0.79
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biol Ther (2012) 0.79
Cancer Cell Invasion in Three-dimensional Collagen Is Regulated Differentially by Gα13 Protein and Discoidin Domain Receptor 1-Par3 Protein Signaling. J Biol Chem (2015) 0.79
Influence of the microenvironment on cell fate determination and migration. Physiol Genomics (2014) 0.78
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Taking cell-matrix adhesions to the third dimension. Science (2001) 15.21
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (2007) 12.42
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev (2007) 10.15
Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol (2002) 5.73
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Emerging roles of proteases in tumour suppression. Nat Rev Cancer (2007) 3.81
Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J (2009) 3.11
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res (2008) 2.19
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res (2004) 1.83
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res (2009) 1.73
HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol (2009) 1.65
Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res (2005) 1.64
Invasion and metastasis in pancreatic cancer. Mol Cancer (2003) 1.61
Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase. Mol Biol Cell (2008) 1.54
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood (2008) 1.52
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res (2005) 1.44
HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol (2008) 1.34
Genomic analysis of smooth muscle cells in 3-dimensional collagen matrix. FASEB J (2002) 1.33
Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol (2003) 1.32
Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther (2006) 1.30
Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res (2006) 1.27
An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer (2003) 1.20
High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res (2005) 1.18
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia (2009) 1.15
Cancer. Breaching the cancer fortress. Science (2009) 1.15
Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression. Oncogene (2010) 1.15
Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res (2003) 1.13
Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol (2008) 1.12
Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. Cancer Res (2007) 1.10
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res (2009) 1.05
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res (2006) 1.04
ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol (2007) 1.01
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res (2005) 1.00
Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther (2008) 0.99
High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer (2008) 0.95
Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene (2005) 0.94
Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res (2000) 0.93
Oncogenic raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells. J Biol Chem (1997) 0.93
Rho-ROCK-myosin signaling mediates membrane type 1 matrix metalloproteinase-induced cellular aggregation of keratinocytes. J Biol Chem (2010) 0.90
High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res (2003) 0.87
The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep (2008) 0.86
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
Extent of surgery affects survival for papillary thyroid cancer. Ann Surg (2007) 4.73
National failure to operate on early stage pancreatic cancer. Ann Surg (2007) 3.65
Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg (2009) 3.07
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Ann Surg (2011) 2.87
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer (2007) 2.85
Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol (2008) 2.74
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst (2008) 2.46
Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA (2013) 2.31
Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg (2014) 2.15
The influence of resident involvement on surgical outcomes. J Am Coll Surg (2011) 2.12
Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg (2008) 2.10
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol (2012) 2.08
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park) (2010) 2.07
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Adherence with postdischarge venous thromboembolism chemoprophylaxis recommendations after colorectal cancer surgery among elderly Medicare beneficiaries. Ann Surg (2014) 1.97
Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst (2009) 1.92
Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol (2009) 1.90
Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg (2008) 1.90
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol (2009) 1.75
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer (2007) 1.63
Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery (2013) 1.62
Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol (2008) 1.60
Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg (2011) 1.59
Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol (2009) 1.58
Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg (2013) 1.56
Risk-based selective referral for cancer surgery: a potential strategy to improve perioperative outcomes. Ann Surg (2010) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A (2010) 1.47
Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg (2008) 1.47
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med (2010) 1.46
Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg (2008) 1.46
Variation in lymph node examination after esophagectomy for cancer in the United States. Arch Surg (2012) 1.46
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg (2007) 1.44
The role of Surgical Champions in the American College of Surgeons National Surgical Quality Improvement Program--a national survey. J Surg Res (2010) 1.43
The significant role of mast cells in cancer. Cancer Metastasis Rev (2011) 1.42
Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg (2007) 1.41
Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg (2008) 1.39
Pancreatic mucinous cystic neoplasm size using CT volumetry, spherical and ellipsoid formulas: validation study. JOP (2014) 1.38
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem (2011) 1.35
Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J (2012) 1.33
Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31
Effect of surgeon training, specialization, and experience on outcomes for cancer surgery: a systematic review of the literature. Ann Surg Oncol (2009) 1.30
Effect of postdischarge morbidity and mortality on comparisons of hospital surgical quality. Ann Surg (2010) 1.30
Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum (2009) 1.29
A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery (2009) 1.27
Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res (2006) 1.27
Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg (2007) 1.25
Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg (2011) 1.25
Surgeons' perceptions of public reporting of hospital and individual surgeon quality. Med Care (2013) 1.22
Adequacy and importance of lymph node evaluation for colon cancer in the elderly. J Am Coll Surg (2007) 1.20
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res (2008) 1.19
Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals. J Gastrointest Surg (2008) 1.18
Slug is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells. J Cell Biochem (2009) 1.18
Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg (2011) 1.17
Validation of new readmission data in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg (2013) 1.15
Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum (2008) 1.15
Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem (2003) 1.14
Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer (2006) 1.14
Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res (2008) 1.14
Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery (2007) 1.13
Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res (2011) 1.13
Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem (2012) 1.12
Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem (2010) 1.12
Laparoscopic versus open resection of gastric gastrointestinal stromal tumors. Am J Clin Oncol (2012) 1.10
Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res (2009) 1.10
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther (2006) 1.09
CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann Surg (2006) 1.06
Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg (2014) 1.06
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas (2008) 1.05
Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg (2008) 1.05
Isoform-specific upregulation of palladin in human and murine pancreas tumors. PLoS One (2010) 1.01
MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling. Mol Cancer Res (2011) 1.00